- Not recommended for pregnant/breastfeeding/preparing women.
(Furthermore, Meglumine may affect the absorption of oral contraceptives; it is recommended to use a non-oral contraceptive method and use contraception for at least 4 weeks.)
- A complete evaluation is required before use for patients with abnormal liver or kidney function, severe gastroparesis, or pancreatic or gallbladder disease.
- Do not use concurrently with other GLP-1 drugs.
- Patients with a history of depression or mood disorders should be closely monitored; if mood deteriorates, a follow-up visit should be made immediately.
